Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Karpeisky

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bioconjugate Chemistry|November 15, 2021
Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with DocetaxelKristen B Farrell, Shawn Zinnen, Douglas H Thamm, et al.
Bone Reports|July 12, 2018
Bisphosphonate conjugation for bone specific drug targetingKristen B Farrell, Alexander Karpeisky, Douglas H Thamm, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2002
Scaleable and efficient synthesis of 2'-deoxy-2'-N-phthaloyl nucleoside phosphoramidites for oligonucleotide synthesisAlexander Karpeisky, David Sweedler, Peter Haeberli, et al.
The Oncologist|November 11, 2018
First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone DiseaseShawn Patrick Zinnen, Alexander Karpeisky, Daniel D Von Hoff, et al.
The Journal of Organic Chemistry|May 14, 2008
Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5'-beta,gamma-methylene and 5'-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidineMikko Ora, Tuomas Lönnberg, Diana Florea-Wang, et al.
Molecules (Basel, Switzerland)|January 25, 2025
Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and DogsJost Klawitter, Mckay Easton, Alexander Karpeisky, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bioconjugate Chemistry|November 15, 2021
Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with DocetaxelKristen B Farrell, Shawn Zinnen, Douglas H Thamm, et al.
Bone Reports|July 12, 2018
Bisphosphonate conjugation for bone specific drug targetingKristen B Farrell, Alexander Karpeisky, Douglas H Thamm, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2002
Scaleable and efficient synthesis of 2'-deoxy-2'-N-phthaloyl nucleoside phosphoramidites for oligonucleotide synthesisAlexander Karpeisky, David Sweedler, Peter Haeberli, et al.
The Oncologist|November 11, 2018
First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone DiseaseShawn Patrick Zinnen, Alexander Karpeisky, Daniel D Von Hoff, et al.
The Journal of Organic Chemistry|May 14, 2008
Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5'-beta,gamma-methylene and 5'-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidineMikko Ora, Tuomas Lönnberg, Diana Florea-Wang, et al.
Molecules (Basel, Switzerland)|January 25, 2025
Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and DogsJost Klawitter, Mckay Easton, Alexander Karpeisky, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
Pageof 1